Skip to main content

Table 1 Literature review of adult Burkitt lymphoma with obstructive symptoms

From: Recurrent small bowel obstruction caused by Burkitt lymphoma in an elderly man: a case report and review of the literature

Author

Age (yr)

Sex

BL type

Presentation

Abdominal syndrome

Syndrome recurrence

Treatment regimen

Outcome

Fernandes et al. [20]

21

Female

Sporadic

Abdominal pain

Intussusception

Yes

Resection alone

NR

Simson et al. [21]

22

Female

Sporadic

Persistent abdominal pain, appendicitis

Appendicitis then intussusception

No

Resection with adjuvant chemotherapy

NR

Sharma et al. [22]

26

Male

HIV

Viral syndrome, abdominal distention

Obstruction

No

Resection then R-CODOX-M/IVAC

NR

Wetter et al. [23]

29

Female

HIV

Abdominal pain

Intussusception

No

Resection

NR

Gupta et al. [24]

33

Female

HIV

Loose stool, abdominal discomfort, nausea, obstructive jaundice

Obstructive jaundice

No

CODOX-M/IVAC

Complete remission

Felix et al. [25]

34

Male

NR

Abdominal pain

Intussusception

Yes

Resection

NR

Özant et al. [26]

37

Female

Sporadic

Abdominal pain, nausea, vomiting

Obstruction due to intussusception

No

Resection with hyperCVAD

Complete remission

Mizutani et al. [27]

38

Male

NR

Abdominal pain

Obstruction

No

Cyclophosphamide and doxorubicin with R-CODOX-M/IVAC

Complete remission

Zerwas et al. [28]

52

Male

NR

Abdominal pain, nausea, vomiting

Intussusception

NR

Resection

NR

Kasparian et al. [this report]

78

Male

Sporadic

Abdominal pain, nausea, vomiting

Obstruction

Yes

Resection then DA-EPOCHR

Complete remission

  1. This is the first reported case of BL presenting with recurrent SBO in the geriatric population
  2. Abbreviations: DA-EPOCHR Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, hydroxydaunorubicin, and rituximab, HIV Human immunodeficiency virus, hyperCVAD Cyclophosphamide, vincristine, doxorubicin, NR Not reported, (R) CODOX-M /IVAC (Rituximab) cyclophosphamide, vincristine, doxorubicin, and high-dose methotrexate, with intrathecal methotrexate, alternating with ifosfamide, etoposide, and cytarabine-A